Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in chinese valve replacement patients

Journal of Cardiothoracic Surgery

Volumn 7, Issue 1, 2012, Pages

  Li, Jie Hui ^a,b,d   Ma, Guo Guo ^c   Zhu, Shu Qiang ^d   Yan, Hao ^d   Wu, Yong Bing ^d   Xu, Jian Jun ^d  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b FUWAI HOSPITAL   (China)

^c HENAN UNIVERSITY OF TECHNOLOGY   (China)

^d NANCHANG UNIVERSITY   (China)

Author keywords

CYP4F2; Implant; INR; SNP; Valve; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450; WARFARIN;

ADULT; ARTICLE; CHINA; COHORT ANALYSIS; FEMALE; GENETICS; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

ADULT; ANTICOAGULANTS; CHINA; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEART VALVE PROSTHESIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOSIS; WARFARIN;

EID: 84866706420     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-7-97     Document Type: Article

References (20)

1. Kidane AG, Burriesci G, Cornejo P, Dooley A, Sarkar S, Bonhoeffer P, Edirisinghe M, Seifalian AM. Current developments and future prospects for heart valve replacement therapy. J Biomed Mater Res B Appl Biomater 2009, 88:290-303.
2. Glurich I, Burmester JK, Caldwell MD. Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev 2010, 15:239-248. 10.1007/s10741-008-9115-9, 18998206.
3. Kikuta Y, Miyauchi Y, Kusunose E, Kusunose M. Expression and molecular cloning of human liver leukotriene B4 omega-hydroxylase (CYP4F2) gene. DNA Cell Biol 1999, 18:723-730. 10.1089/104454999315006, 10492403.
4. Arellano-Rodrigo E. Home monitoring of warfarin effects. N Engl J Med 2011, 364:378-379.
5. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005, 127:2049-2056. 10.1378/chest.127.6.2049, 15947319.
6. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 2008, 10:89-98. 10.1097/GIM.0b013e31815bf924, 18281915.
7. Nakai K, Tsuboi J, Okabayashi H, Fukuhiro Y, Oka T, Habano W, Fukushima N, Nakai K, Obara W, Fujioka T, Suwabe A, Gurwitz D. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 2007, 8:713-719. 10.2217/14622416.8.7.713, 18240904.
8. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333. 10.1182/blood-2005-03-1108, 15947090.
9. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res 2010, 125:e159-e166. 10.1016/j.thromres.2009.10.017, 19942260.
10. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112. 10.1182/blood-2007-11-122010, 2288721, 18250228.
11. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ. A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 2010, 70:234-240. 10.1111/j.1365-2125.2010.03698.x, 2911553, 20653676.
12. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433. 10.1371/journal.pgen.1000433, 2652833, 19300499.
13. Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahé I, Legendre C, Taillandier-Hériche E, Durand-Gasselin B, Houllier AM, Verrier P, Beaune P, Loriot MA, Siguret V. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010, 87:57-64. 10.1038/clpt.2009.178, 19794411.
14. Pérez-Andreu V, Roldán V, López-Fernández MF, Antón AI, Alberca I, Corral J, Montes R, García-Barberá N, Ferrando F, Vicente V, González-Conejero R. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost 2010, 8:1012-1017.
15. Kringen MK, Haug KB, Grimholt RM, Stormo C, Narum S, Opdal MS, Fosen JT, Piehler AP, Johansen PW, Seljeflot I, Berg JP, Brørs O. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol 2011, 2011:739751. 2992873, 21127708.
16. Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 2007, 8:851-861. 10.2217/14622416.8.7.851, 18240910.
17. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009, 75:1337-1346. 10.1124/mol.109.054833, 2684883, 19297519.
18. Wells PS, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, Taljaard M. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res 2010, 125:e259-e264. 10.1016/j.thromres.2009.11.020, 20421126.
19. Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, Chen YT. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009, 10:1905-1913. 10.2217/pgs.09.106, 19958090.
20. Liang R, Wang C, Zhao H, Huang J, Hu D, Sun Y. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res 2011, 130:38-44.